Oruka Therapeutics
ORKA
19 hedge funds and large institutions have $4.53M invested in Oruka Therapeutics in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 4 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
12% more funds holding
Funds holding: 17 → 19 (+2)
9% more capital invested
Capital invested by funds: $4.16M → $4.53M (+$361K)
0.19% more ownership
Funds ownership: 0.69% → 0.88% (+0.19%)
96% less call options, than puts
Call options by funds: $18K | Put options by funds: $419K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$959K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$57.8K |
| 3 |
AGM
Alpine Global Management
New York
|
+$51.5K |
| 4 |
Millennium Management
New York
|
+$48.9K |
| 5 |
MA
Minerva Advisors
Bala Cynwyd,
Pennsylvania
|
+$30.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$71.4K |
| 2 |
Goldman Sachs
New York
|
-$49K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$38K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$19K |
| 5 |
BlackRock
New York
|
-$15.6K |
ORKA Hedge Fund Activity: Q3 2021 in Review
19 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q3 2021, worth a combined $4.53M — up 8.7% from $4.16M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ORKA positions and 4 closed out — a net gain of 2 holders — while 7 added to existing stakes and 4 trimmed.
The largest buyer was GSA Capital Partners, adding an estimated $959K. The largest seller was Citadel Advisors, cutting an estimated $71.4K.
- 19 institutional investors held Oruka Therapeutics (ORKA) as of Q3 2021, up from 17 in Q2 2021.
- Funds reported $4.53M of Oruka Therapeutics stock for Q3 2021, up 8.7% quarter-over-quarter.
- 6 funds opened new Oruka Therapeutics positions in Q3 2021 and 4 closed out, a net change of +2 holders.
- The largest Oruka Therapeutics buyer in Q3 2021 was GSA Capital Partners, an estimated $959K added.
- The largest Oruka Therapeutics seller in Q3 2021 was Citadel Advisors, an estimated $71.4K sold.
Based on aggregated 13F filings for Q3 2021.